Stefan Seregard/Anders Kvanta´s research group

Denna sida på svenska

Retina, eye oncology

The research team is led by Professor Stefan Seregard and Professor Anders Kvanta. Activities include both projects with a focus on eye cancer, and primarily malignant melanoma, and projects focusing focusing on the retina and related disease.

Both the clinical management and the histopathological evaluation of eye melanoma have been centralized at St. Erik's Eye Hospital for a long time. This has enabled a number of different projects, which both have clinical orientation, such as studies of various types of brachytherapy (radiation from applicators) to more experimental studies that include cell lines, animal models and studies of histopathological material. The experimental studies are at present mainly focused on the understanding of the molecular mechanisms that are important for the occurrence of eye melanoma, but also for studies aiming to find an effective treatment of advanced disease.

The clinical studies on the retina of the eye are focused on identifying and improving treatments of our most common retinal diseases. Several studies are conducted with the goal to halt complications of pathologic neovascularisation in macular degeneration, retinal vein occlusion and diabetic retinopathy. In a joint translational project we will use differentiated embryonal stem cells to regenerate the macula in an attempt to treat the severe dry form of macular degeneration. Our experimental projects include molecular- and cell biologic studies and preclinical animal models and aim to identify new molecules relevant to the onset of neovascularisation and cell death for these common retinal conditions.

Research Projects

  • Cancer in the eye, malignant melanoma
  • Basic research on ocular angiogenesis
  • Stemcell treatment in retinal disease
  • Macular degeneration
  • Ischemic retinopathies
  • Vitreoretinal surgery

Selected Publications

Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study.
Epstein D, Algvere P, von Wendt G, Seregard S, Kvanta A
Ophthalmology 2012 Jun;119(6):1184-9

Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-month prospective randomised clinical study.
Söderberg A, Algvere P, Hengstler J, Söderberg P, Seregard S, Kvanta A
Br J Ophthalmol 2012 May;96(5):714-8

Nuclear HER3 is associated with favorable overall survival in uveal melanoma.
Trocmé E, Mougiakakos D, Johansson C, All-Eriksson C, Economou M, Larsson O, et al
Int. J. Cancer 2012 Mar;130(5):1120-7

Intraoperative mitomycin C versus autologous conjunctival autograft in surgery of primary pterygium with four-year follow-up.
Koranyi G, Artzén D, Seregard S, Kopp E
Acta Ophthalmol 2012 May;90(3):266-70

Expression and prognostic significance of iNOS in uveal melanoma.
Johansson C, Mougiakakos D, Trocme E, All-Ericsson C, Economou M, Larsson O, et al
Int. J. Cancer 2010 Jun;126(11):2682-9

Group members

Anders KvantaResearch team leader, Adjunct professor
Charlotta All-EricssonAssociated
David Leo Joakim EpsteinAssociated
Hammurabi BartumaAssociated, Postdoc
Helder AndreAssociated
Jóhann GudmundssonGraduate Student
Katarina BartumaAssociated, Postdoc
Lena IvertAssociated
Manuel Casselholm De SallesGraduate Student
Maria FiliGraduate Student
Monika GrudzinskaAssociated, Postdoc
Parviz MammadzadaGraduate Student
Sandra Petrus-ReurerGraduate Student
Stefan SeregardResearch team leader, Professor/senior physician
Urban ErikssonAssociated, Postdoc